APR 10, 2019 11:45 AM PDT

Dovato: Approved Drug for HIV-1

WRITTEN BY: Nouran Amin

Roughly 1.1 million people in the U.S. live with HIV with 15 percent of that population unaware they are infected. Treating these individuals must be highly effective to suppress the viral load in the blood that is needed to prevent disease progression. Now, the U.S. Food and Drug Administration has granted approval for the two-drug, fixed-dose, complete regimen for HIV-infected adults—the drug is called Dovato (dolutegravir and lamivudine).

“Currently, the standard of care for patients who have never been treated is a three-drug regimen. With this approval, patients who have never been treated have the option of taking a two-drug regimen in a single tablet while eliminating additional toxicity and potential drug interactions from a third drug,” said Debra Birnkrant, M.D., Director of the Division of Antiviral Products. “Having a drug-sparing treatment available that uses fewer drugs is beneficial to patients who may have issues taking multiple medications over a long period of time.”

Dovato was proven successful in clinical trials when the treatment maintained low-levels (less than 50 copies/mL) of HIV RNA in the blood for at least 48 weeks.

However, Dovato comes with warning to those patients infected with both HIV and hepatitis B—that they must seek additional treatment for their hepatitis B or possibly a different drug regimen. Additionally, those patients with both HIV and hepatitis B who take other treatments containing lamivudine--an ingredient in Dovato--have developed variants of hepatitis B that is associated with resistance to lamivudine and may cause severe liver problems, including liver failure after they stop taking stop taking drugs containing lamivudine. Therefore, patients with HIV and hepatitis B virus, who stop using Dovato, should closely monitor with their physician.

Additionally, patients are strongly recommend to avoid Dovato treatment at the time of conception through the first trimester of pregnancy because there is a known risk for neural tube defects with dolutegravir. Other adverse effects of Dovato include most commonly headache, diarrhea, nausea, insomnia and fatigue.

The approval of Dovato was granted to ViiV Healthcare.

Source: FDA

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 09, 2018
Drug Discovery
DEC 09, 2018
Insect Venom Can Someday Combat Antibiotic-Resistant Infections
Insect venom, such as those secreted by wasps and bees, are considered an insect’s immune system defense because of its richness in bacterial killing...
JAN 20, 2019
Drug Discovery
JAN 20, 2019
Multiple sclerosis treatments hold long-term benefits
An international study, led by the Clinical Outcomes Research unit (CORe) at Royal Melbourne Hospital and University of Melbourne, concludes the importance...
JAN 23, 2019
Cardiology
JAN 23, 2019
New Discoveries Bring Us Closer To Eliminating Heart Attacks
A host of new discoveries bring medicine closer to the goal of ending heart attacks. These include new protective methods that can help identify those at r...
JAN 23, 2019
Drug Discovery
JAN 23, 2019
Frequent Aspirin Use Can Lead to Increased Bleeding
According to a systemic study published in the Journal of the American Medical Association (JAMA), taking aspirin regularly may prevent heart attacks and s...
FEB 27, 2019
Immunology
FEB 27, 2019
Anti-Inflammatory Meds without Side Effects, Please
Drugs such as ibuprofen or aspirin that relieve pain and lower fever are among the most frequently used drugs worldwide....
MAR 10, 2019
Microbiology
MAR 10, 2019
Bacteria on Frog Skin Can Help Fight Fungal Infections
In recent years, fungal disease has decimated amphibian populations; some species went extinct. But others withstood the epidemic....
Loading Comments...